Z Zilahi

Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study

Jonathan P. Piccini, Valeria Caso, Stuart J. Connolly et al. · The Lancet · 2022 · 311 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +11

Initiating Sacubitril/Valsartan (LCZ696) in Heart Failure: Results of TITRATION, a Double-Blind, Randomized Comparison of Two Uptitration Regimens

Michele Senni, John J.V. McMurray, Rolf Wachter et al. · European Journal of Heart Failure · 2016 · 236 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16

Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial

Deepak L. Bhatt, Philippe Gabríel Steg, Shamir R Mehta et al. · The Lancet · 2019 · 210 citations · Full text

Medicine, Cardiology, Pharmacotherapy +15

Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium–Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis

Peter Rossing, Stefan D. Anker, Gerasimos Filippatos et al. · Diabetes Care · 2022 · 199 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

QT Dispersion in Patients with End-Stage Renal Failure and during Hemodialysis

ISTVÁN LŐORINCZ, János Mátyus, Z Zilahi et al. · Journal of the American Society of Nephrology · 1999 · 121 citations

Medicine, Cardiology, Nephrology +13